Cargando…

Improved pathology reporting in NAFLD/NASH for clinical trials

Detalles Bibliográficos
Autores principales:	Langford, Caitlin Rose, Goldinger, Marc H, Treanor, Darren, McGenity, Clare, Dillman, Jonathan R, Allende, Daniela S, Goldin, Robert, Brunt, Elizabeth M, Zatloukal, Kurt, Denk, Helmut, Fleming, Kenneth A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788244/ https://www.ncbi.nlm.nih.gov/pubmed/34753791 http://dx.doi.org/10.1136/jclinpath-2021-207967

Ejemplares similares

Reporting of Artificial Intelligence Diagnostic Accuracy Studies in Pathology Abstracts: Compliance with STARD for Abstracts Guidelines
por: McGenity, Clare, et al.
Publicado: (2022)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Tripartite motif 38 alleviates the pathological process of NAFLD–NASH by promoting TAB2 degradation
por: Yao, Xinxin, et al.
Publicado: (2023)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

From the origin of NASH to the future of metabolic fatty liver disease
por: Geier, Andreas, et al.
Publicado: (2021)

Priming, Triggering, Adaptation and Senescence (PTAS): A Hypothesis for a Common Damage Mechanism of Steatohepatitis
por: Abuja, Peter M., et al.
Publicado: (2021)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

SAT-LB004 Therapeutic Potential of LPCN 1144 in NAFLD and NASH
por: Baker, Jonathan, et al.
Publicado: (2019)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
por: Piras, Cristina, et al.
Publicado: (2021)

Non-Invasive Risk Stratification in NAFLD/NASH Patients for Screening EGD
por: Romano, John, et al.
Publicado: (2022)

Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction
por: Guo, Mingwei, et al.
Publicado: (2022)

Causability and explainability of artificial intelligence in medicine
por: Holzinger, Andreas, et al.
Publicado: (2019)

Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
por: Dongiovanni, Paola, et al.
Publicado: (2013)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
por: Kořínková, L., et al.
Publicado: (2020)

Effect of exercise and diet intervention in NAFLD and NASH via GAB2 methylation
por: Wu, Na, et al.
Publicado: (2021)

Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
por: Finotti, Michele, et al.
Publicado: (2021)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

Differences in NAFLD/NASH Management by Provider Specialty: Opportunities for Optimizing Multidisciplinary Care
por: Porayko, Michael K, et al.
Publicado: (2022)

Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies
por: Heinemann, Fabian, et al.
Publicado: (2022)

A continuous-time Markov chain model of fibrosis progression in NAFLD and NASH
por: Meyer, Lyndsey F., et al.
Publicado: (2023)

Clinical Trial Data Sharing for COVID-19–Related Research
por: Dron, Louis, et al.
Publicado: (2021)

Biobanking in the digital pathology era
por: BONIZZI, GIUSEPPINA, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4lugs7o2b9a732s8ul774mddk7